Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
For the design of potent subunit vaccines, it is of paramount importance to identify all antigens immunologically recognized by a patient population infected with a pathogen. We have developed a rapid and efficient procedure to identify such commonly recognized antigens, and here we provide a comprehensive in vivo antigenic profile of Staphylococcus aureus , an important human pathogen. S. aureus peptides were displayed on the surface of Escherichia coli via fusion to one of two outer membrane proteins (LamB and FhuA) and probed with sera selected for high Ab titer and opsonic activity. A total of 60 antigenic proteins were identified, most of which are located or predicted to be located on the surface of the bacterium or secreted. The identification of these antigens and their reactivity with individual sera from patients and healthy individuals greatly facilitate the selection of promising vaccine candidates for further evaluation. This approach, which makes use of whole genome sequence information, has the potential to greatly accelerate and facilitate the formulation of novel vaccines and is applicable to any pathogen that induces Abs in humans and/or experimental animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The haptoglobin-hemoglobin complex is also a viable source of iron for S. aureus and this complex is bound by IsdH (25, 27, 78) (Fig 1. B).”
From Molecular Mechanisms of Staphylococcus aureus Iron Acquisition (2011) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome Sequencing
Pizza, M., Scarlato, V., Masignani, V., Giuliani, M. M., Aricò, B., Comanducci, M., Jennings, G. T., Baldi, L., Bartolini, E., Capecchi, B., et al. (2000) · Science · doi:10.1126/science.287.5459.1816 · Cited by 1,399
Navarre, W. W., & Schneewind, O. (1999) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.63.1.174-229.1999 · Cited by 1,391
Wizemann, T. M., Heinrichs, J. H., Adamou, J. E., Erwin, A. L., Kunsch, C., Choi, G. H., Barash, S. C., Rosen, C. A., Masure, H. R., Tuomanen, E., et al. (2001) · Infection and Immunity · doi:10.1128/iai.69.3.1593-1598.2001 · Cited by 351
Jungblut, P. R., Schaible, U. E., Mollenkopf, H. ‐., Zimny‐Arndt, U., Raupach, B., Mattow, J., Halada, P., Lamer, S., Hagens, K., & Kaufmann, S. H. E. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01549.x · Cited by 327
Folgori, A., Tafi, R., Meola, A., Felici, F., Galfré, G., Cortese, R., Monaci, P., & Nicosia, A. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06501.x · Cited by 250
Kemp, D. J., Coppel, R. L., Cowman, A. F., Saint, R. B., Brown, G. V., & Anders, R. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3787 · Cited by 209
Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes
Mamula, M. J., & Mamula, M. J. (1998) · Immunological Reviews · doi:10.1111/j.1600-065x.1998.tb01223.x · Cited by 116
Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)
Snoeck, R., Noël, J., Muller, C., Clercq, E. D., & Bossens, M. (2000) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(200002)60:2<144::aid-jmv7>3.0.co;2-g · Cited by 112
Chakravarti, D. N., Fiske, M. J., Fletcher, L. D., & Zagursky, R. J. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00256-5 · Cited by 108
Rennermalm, A., Li, Y., Bohaufs, L., Jarstrand, C., Brauner, A., Brennan, F. R., & Flock, J. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00080-9 · Cited by 101
Research works printed but not linked: 2
- Pereboeva L A, Pereboev A V, Wang L F, Morris G E. J Med Virol. 2000;60:144–151. [PubMed] [Google Scholar]
- Lorenz U, Ohlsen K, Karch H, Thiede A, Hacker J. FEMS Immunol Med Microbiol. 2000;29:145–153. doi: 10.1111/j.1574-695X.2000.tb01517.x. [DOI] [PubMed] [Google Scholar] · doi:10.1111/j.1574-695x.2000.tb01517.x · Paper page
Cited by
Items 101–200 of 218
Hierarchy of human IgG recognition within the Staphylococcus aureus immunome
Radke, E. E., Brown, S. M., Pelzek, A. J., Fulmer, Y., Hernandez, D. N., Torres, V. J., Thomsen, I. P., Chiang, W. K., Miller, A. O., Shopsin, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31424-3 · Cited by 32
Lattanzi, M., & Rappuoli, R. (2005) · Birkhäuser Basel eBooks · doi:10.1007/3-7643-7381-4_5 · Cited by 33
“To identify vaccine candidates for Staphylococcus aureus, an approach based on genomic peptide libraries and well-characterized human sera was developed [80] .”
BackgroundBumann, D., Holland, P., Siejak, F., Koesling, J., Sabarth, N., Lamer, S., Zimny‐Arndt, U., Jungblut, P. R., & Meyer, T. F. (2002) · Infection and Immunity · doi:10.1128/iai.70.11.6494-6498.2002 · Cited by 33
“sponses are obviously expressed in situ (4, 9, 26) and become”
BackgroundLi, M., Song, S., Yang, D., Li, C., & Li, G. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.02.023 · Cited by 31
Community-associated Methicillin-resistant Staphylococcus aureus Skin Infections in the Tropics
Tong, S. Y. C., Steer, A. C., Jenney, A. W. J., & Carapetis, J. R. (2010) · Dermatologic Clinics · doi:10.1016/j.det.2010.09.005 · Cited by 32
Human antibody responses against non-covalently cell wall-bound Staphylococcus aureus proteins
Pastrana, F. R., Neef, J., Koedijk, D. G. A. M., de Graaf, D., Duipmans, J. C., Jonkman, M. F., Engelmann, S., van Dijl, J. M., & Buist, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-21724-z · Cited by 31
Söllner, J. (2006) · Journal of Molecular Recognition · doi:10.1002/jmr.770 · Cited by 31
“…classifiers were based on a set of proprietary, putative linear B-cell epitopes derived from numerous bacterial pathogens by means of an experimental selection procedure (Etz et al. , 2002) as well as the two publicly available sources BciPep (Saha et al. , 2005) and FIMM (Schonbach et al. , 2000).”
BackgroundSelf-citationPrevention ofStaphylococcus aureusinfections: advances in vaccine development
Shinefield, H. R., & BLACK, S. B. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.5.669 · Cited by 32
Bacterial genomes pave the way to novel vaccines
Meinke, A. L., Henics, T., & NAGY, E. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.04.008 · Cited by 30
Self-citationSelection of peptide entry motifs by bacterial surface display
Taschner‐Mandl, S., Meinke, A. L., von Gabain, A., & Boyd, A. (2002) · Biochemical Journal · doi:10.1042/bj20020164 · Cited by 28
Self-citationShinefield, H. R. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.126 · Cited by 29
Pourmand, M. R., Clarke, S. R., Schuman, R. F., Mond, J. J., & Foster, S. J. (2006) · Infection and Immunity · doi:10.1128/iai.00521-06 · Cited by 40
“However, this required appropriate cloning of all expressed genes in frame with the fusion protein, and the target proteins had to be amenable to expression in Escherichia coli (11).”
BackgroundCharacteristics of cellular composition of periodontal pockets
Hasiuk, P. А., Hasiuk, N., Kindiy, D. D., Ivanchyshyn, V. V., Kalashnikov, D. V., & Zubchenko, S. (2016) · Interventional Medicine and Applied Science · doi:10.1556/1646.8.2016.4.5 · Cited by 28
“Studies [2, 8, 9] indicate the role of parodontopathogenic microflora such as Actinobacillus actinomycetemcomitans, Bacteroides forsythus, Prevotella intermedia, Porphyromonas gingivalis, Treponema denticola (by polymerase chain reaction), Chlamydia (Chlamydia pneumoniae and Chlamydia trachomatis), Helicobacter pylori…”
BackgroundComparative membrane proteome analysis of three B orrelia species
Gesslbauer, B., Poljak, A., Handwerker, C., Schüler, W., Schwendenwein, D., Weber, C., Lundberg, U., Meinke, A. L., & Kungl, A. J. (2012) · PROTEOMICS · doi:10.1002/pmic.201100211 · Cited by 28
Self-citationAnti-Staphylococcus aureus immunotherapy: current status and prospects
García-Lara, J., & Foster, S. J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.07.008 · Cited by 27
New ways to identify novel bacterial antigens for vaccine development
Movahedi, A., & Hampson, D. J. (2008) · Veterinary Microbiology · doi:10.1016/j.vetmic.2008.02.011 · Cited by 32
Botelho-Nevers, É., Verhoeven, P. O., Paul, S., Grattard, F., Pozzetto, B., Berthelot, P., & Lucht, F. (2013) · Expert Review of Vaccines · doi:10.1586/14760584.2013.840091 · Cited by 27
Wang, R., Arévalo‐Herrera, M., Gardner, M. J., Bonelo, A., Carlton, J. M., Gomez, A., Vera, O., Soto, L., Vergara, J., Bidwell, S. L., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200425807 · Cited by 27
Self-citationStrategies for the development of vaccines conferring broad-spectrum protection
Nagy, G., ̋dy, L. E., & Pál, T. (2008) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2008.01.012 · Cited by 29
Groot, A. S. D. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.767 · Cited by 26
“To mention just a few, immunome-derived vaccines for Neisseria meningitidis [18], Streptococcus pneumoniae [19], Staphylococcus aureus [20,21], Porphyromonas gingivalis [22], group B streptococcus [23] and Chlamydia pneumoniae [24] are in development.”
BackgroundA genomics-based approach to biodefence preparedness
Fraser, C. M. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1245 · Cited by 25
“One of the most important challenges that is facing us today is how to best exploit with this pathogen can immunologically recognize 55 .”
BackgroundSelf-citationSubdominance in Antibody Responses: Implications for Vaccine Development
Lindahl, G. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00078-20 · Cited by 25
Meinke, A. L., Senn, B. M., Visram, Z., Henics, T., Minh, D. B., Schüler, W., Neubauer, C., Gelbmann, D., Noiges, B., Sinzinger, J., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.041 · Cited by 25
Self-citationSerological proteome analysis of Staphylococcus aureus isolated from sub-clinical mastitis
Tedeschi, G., Taverna, F., NEGRI, A., Piccinini, R., Nonnis, S., RONCHI, S., & Zecconi, A. (2008) · Veterinary Microbiology · doi:10.1016/j.vetmic.2008.08.019 · Cited by 24
“…of reproducible proteomic procedures to evaluate the pattern of 206 antibody expressed by infected subjects is considered a valuable tool for the 207 development of vaccines and diagnostic tools (Etz et al., 2002; Sellman et al., 208 2005; Vytvytska et al., 2002; Weichhart et al., 2003).”
MethodBoero, E., Cruz, A. R., Pansegrau, W., Giovani, C., Rooijakkers, S. H. M., van Kessel, K. P. M., van Strijp, J. A. G., Bagnoli, F., & Manetti, A. G. O. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834711 · Cited by 31
Lawrence, P. K., Rokbi, B., Arnaud-Barbe, N., Sutten, E. L., Norimine, J., Lahmers, K. K., & Brown, W. C. (2012) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05642-11 · Cited by 27
“Identification of potential vaccine antigens using patient infection serum is a common strategy (19, 94) although the usefulness of this strategy for S.”
BackgroundProteomics, Bioinformatics and Structure-Function Antigen Mining For Gonorrhea Vaccines
Baarda, B. I., Martinez, F. G., & Sikora, A. E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02793 · Cited by 25
Vaccines and Immunoinformatics for Vaccine Design
Joon, S., Singla, R. K., & Shen, B. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-16-8969-7_5 · Cited by 21
Proteomics-based Expression Library Screening (PELS)
Kudva, I. T., Krastins, B., Sheng, H., Griffin, R. W., Sarracino, D. A., Tarr, P. I., Hovde, C. J., Calderwood, S. B., & John, M. (2006) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t600013-mcp200 · Cited by 21
“However, colony immunoscreening and in vivo induced antigen technology (IVIAT) (1), a variation of colony immunoscreening that defines only partial immunoproteomes, and bacterial surface display coupled with magnetic cell sorting (2) are laborious and require several months or more for definitive IMP identification.”
BackgroundApplication of genomics in bacterial vaccine discovery: a decade in review
Zagursky, R. J., & ANDERSON, A. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.009 · Cited by 23
Henics, T., Winkler, B., Pfeifer, U., Gill, S. R., Buschle, M., von Gabain, A., & Meinke, A. L. (2003) · BioTechniques · doi:10.2144/03351dd03 · Cited by 21
Self-citationRewiring Gram-Negative Bacteria Cell Surfaces with Bio-Orthogonal Chemistry via Liposome Fusion
Elahipanah, S., Radmanesh, P., Luo, W., O’Brien, P. J., Rogozhnikov, D., & Yousaf, M. N. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00073 · Cited by 20
Identification of candidate genes for in vitro androgenesis induction in maize
Barret, P., Brinkman, M., Dufour, P., Murigneux, A., & Beckert, M. (2004) · Theoretical and Applied Genetics · doi:10.1007/s00122-004-1792-8 · Cited by 20
Poljak, A., Comstedt, P., Hanner, M., Schüler, W., Meinke, A. L., Wizel, B., & Lundberg, U. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.10.073 · Cited by 19
Self-citationCui, J.-C., Hu, D., Lin, Y.-C., Ai-dong, Q., & Nakane, A. (2005) · FEMS Immunology & Medical Microbiology · doi:10.1016/j.femsim.2005.01.010 · Cited by 19
“aureus infection and demonstrates the need for other means of controlling and preventing staphylococcal infections [5–7].”
BackgroundGenetic basis of neonatal methicillin‐resistant Staphylococcus aureus in Japan
Kikuchi, K. (2003) · Pediatrics International · doi:10.1046/j.1442-200x.2003.01720.x · Cited by 20
Huda, T. M., Nair, H., Τheodoratou, E., Zgaga, L., Fattom, A., Arifeen, S. E., Rubens, C. E., Campbell, H. J., & Rudan, I. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-s3-s27 · Cited by 18
“aureus bacteraemia [29] to evaluate the efficacy of Tefibazumab (Aurexis).”
BackgroundHoltfreter, S., Kolata, J., Stentzel, S., Bauerfeind, S. S., Schmidt, F., Sundaramoorthy, N., & Bröker, B. M. (2016) · Proteomes · doi:10.3390/proteomes4010011 · Cited by 19
“aureus antigens that are recognized by antibodies [160].”
BackgroundDelfani, S., Mobarez, A. M., Fooladi, A. A. I., Amani, J., & Emaneini, M. (2015) · Medical Microbiology and Immunology · doi:10.1007/s00430-015-0425-y · Cited by 19
“We choose ClfA, IsdB and Hlg proteins, because it was shown in previous attempts that these three virulence factors can produce an immune response that promotes opsonophagocytic activity [1, 10, 13, 18, 32, 33].”
MethodAntistaphylococcal Vaccines and Immunoglobulins
Deresinski, S. C. (2006) · Drugs · doi:10.2165/00003495-200666140-00002 · Cited by 18
Knaust, A., & Frosch, M. (2004) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2004.07.008 · Cited by 18
Oesterreich, B., Lorenz, B., Schmitter, T., Kontermann, R. E., Zenn, M., Zimmermann, B., Haake, M., Lorenz, U., & Ohlsen, K. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.27692 · Cited by 23
“Therefore, we selected the lytic transglycosylase IsaA as target antigen for immunotherapy due to its outstanding immunodominance during infection.(7,10,23) Here, we confirmed binding of the humanized hUK-66 IgG1 to IsaA expressed by major clinical and community-associated MRSA lineages including CC5, CC8, CC22, CC45,…”
BackgroundComposition of the ANTIGENome of Helicobacter pylori defined by human serum antibodies
Meinke, A. L., Storm, M., Henics, T., Gelbmann, D., Prustomersky, S., Kovács, Z., Minh, D. B., Noiges, B., Stierschneider, U., & Berger, M. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.066 · Cited by 17
Self-citationHermans, K., Devriese, L. A., & Haesebrouck, F. (2010) · doi:10.1002/9780470958209.ch5 · Cited by 17
Omics‐Based Systems Vaccinology for Vaccine Target Identification
He, Y. O. (2012) · Drug Development Research · doi:10.1002/ddr.21049 · Cited by 16
Pooled Protein Immunization for Identification of Cell Surface Antigens in Streptococcus sanguinis
Ge, X., Kitten, T. O., Munro, C. L., Conrad, D. H., & Xu, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011666 · Cited by 17
“This approach was first successfully applied to identify vaccine candidates in Neisseria meningitidis [2] and has since been applied to identify vaccine candidates for other bacterial pathogens including Streptococcus pneumoniae [4], Streptococcus agalactiae [5], Staphylococcus aureus [6], Porphyromonas gingivalis [7]…”
BackgroundCouto, N., Martins, J., Lourenço, A. M., Pomba, C., & Coelho, A. V. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.12.017 · Cited by 16
Michie, C. A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02270-6 · Cited by 16
Anti-infective antibodies: a novel tool to prevent and treat nosocomial diseases
Nagy, E., Giefing, C., & von Gabain, A. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.1.21 · Cited by 15
Self-citationRaedler, M., Heyne, S., Wagner, E., Shalkowski, S. K., Secore, S., Anderson, A. S., Cook, J. C., Cope, L. D., McNeely, T. B., Retzlaff, M., et al. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00478-08 · Cited by 14
“aureus strains (11) and represent good targets for drug and vaccine development.”
BackgroundHossainy, S., Kang, S., Medellin, J. E. G., Alpar, A. T., Refvik, K. C., Yoyo, Y., Vuong, I., Chang, K., Wang, T., Solanki, A., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01469-7 · Cited by 17
Senn, B. M., Visram, Z., Meinke, A. L., Neubauer, C., Gelbmann, D., Sinzinger, J., Hanner, M., Lundberg, U., Boisvert, H., Reinscheid, D. J., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.03.100 · Cited by 13
Self-citationHaghighat, S., Siadat, S. D., Rezayat, S. M., Sepahi, A. A., & Mahdavi, M. (2013) · PubMed Central · Cited by 12
Veerapandian, R., Shanmughapriya, S., Murugesan, K., Artiushin, S., Velineni, S., Timoney, J. F., & Natarajaseenivasan, K. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00509-15 · Cited by 13
Will we ever see the approval of aStaphylococcus aureusvaccine?
Patti, J. M. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.99 · Cited by 11
Overcoming Immune Evasion in Staphylococcus aureus : Strategies for Rational Vaccine Design
Shinwari, K., Vieira, B., Ciaparin, I., Håkansson, A., Darrieux, M., & Converso, T. R. (2025) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00569 · Cited by 12
Staphylococcal Infection, Antibiotic Resistance and Therapeutics
Choudhury, R., Panda, S., Sharma, S., & V., D. (2012) · InTech eBooks · doi:10.5772/29395 · Cited by 12
“…of a wide range of surface and extracellular target antigens such as IsdB, GrfA, IsaA, IsaB, Atl, IsdA, IsdH, www.intechopen.com Staphylococcal Infection, Antibiotic Resistance and Therapeutics 257 FmtB, SspA, SspB and Lip (Lorenz et al., 2000, Etz et al., 2002, Clarke and Foster, 2006).”
BackgroundHaas, M. (2003) · Human Pathology · doi:10.1016/j.humpath.2003.10.001 · Cited by 9
Exploring and Exploiting Bacterial Proteomes
Cordwell, S. J. (2004) · Humana Press eBooks · doi:10.1385/1-59259-763-7:115 · Cited by 9
Naz, K., Ullah, N., Naz, A., Irum, S., Dar, H. A., Zaheer, T., Shahid, F., & Ali, A. (2021) · Current Proteomics · doi:10.2174/1570164618666210212122847 · Cited by 9
Carabarín‐Lima, A., Rodríguez-Morales, O., González‐Vázquez, M. C., Baylón-Pacheco, L., Reyes, P. A., Arce-Fonseca, M., & Rosales‐Encina, J. L. (2014) · Parasitology Research · doi:10.1007/s00436-013-3737-0 · Cited by 9
“…together have contributed to the emergence of the reverse vaccinology (He and Xiang 2013), with which it has been possible to appoint several vaccine candidates for human pathogens (Etz et al. 2002; Gan et al. 2010; Liu et al. 2009; Maione et al. 2005; Montigiani et al. 2002; Wizemann et al. 2001).”
BackgroundAdvanced strategies for development of vaccines against human bacterial pathogens
Sharma, A., Sanduja, P., Anand, A., Mahajan, P., Guzmán, C. A., Yadav, P., Awasthi, A., Hanski, E., Dua, M., & Johri, A. K. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03021-6 · Cited by 11
Rasmussen, K. J., Mattsson, A. H., Pilely, K., Asferg, C. A., Ciofu, O., Vitved, L., Koch, C., & Kemp, M. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.07.016 · Cited by 7
Nabi, G., McLaughlin, R. W., Khan, S., Hao, Y., & Chang, M. X. (2020) · Animal Health Research Reviews · doi:10.1017/s1466252320000158 · Cited by 7
“Furthermore, a new technology called ‘ANTIGENome’ which combines the power of serological antigen identification and full genome coverage (Etz et al., 2002) could be used to directly validate antigens without the need for recombinant protein expression.”
BackgroundKylväjä, R., Kankainen, M., Holm, L., & Westerlund‐Wikström, B. (2011) · BMC Microbiology · doi:10.1186/1471-2180-11-117 · Cited by 7
“aureus epitopes recognized by human antibodies and for the identification of peptide motifs that mediate entry into eukaryotic cells [20-22].”
BackgroundThe Antigenome: From Protein Subunit Vaccines to Antibody Treatments of Bacterial Infections?
Giefing, C., Nagy, E., & von Gabain, A. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1132-2_9 · Cited by 8
Self-citationBhakta, S., Choudhury, S., Paul, J., & Bhattacharya, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85844-1.00006-4 · Cited by 9
Häupl, T., Burmester, G. R., & Stuhlmüller, B. (2002) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-002-0432-4 · Cited by 6
“Auch Untersuchungen der humoralen Immunitätslage gegen Erreger wird mit entsprechenden bakteriellen Antigenen untersucht mit dem Ziel, potente Impfstoffantigen daraus abzuleiten (15, 61).”
BackgroundVaccinology: The art of putting together the right ingredients
Grandi, A., Tomasi, M., & Grandi, G. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1123829 · Cited by 6
Characterization of Novel Antibiotic Resistance Genes in Staphylococcal aureus
Ahmad, S. (2018) · Journal of Bacteriology & Mycology Open Access · doi:10.15406/jbmoa.2018.06.00167 · Cited by 9
“There has been a transformed attention in the characterization of essential components of serious biosynthetic pathways (fatty acid biosynthesis or peptidoglycan assembly) as potential targets [18].”
BackgroundAntibacterial Vaccine Research in 21st Century: From Inoculation to Genomics Approaches
Altındiş, E. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660188 · Cited by 5
Molecular Approaches to Bacterial Vaccines
Леонидович, М. В., & Torres, A. G. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-369408-9.00006-8 · Cited by 6
Reverse vaccinology: An approach to search vaccine leads of Shigella sonnei
Anand, Y., Pande, S. S., & Gore, D. (2013) · Journal of Pharmacy Research · doi:10.1016/j.jopr.2013.07.030 · Cited by 5
Computational Peptide Vaccinology
Söllner, J. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-2285-7_13 · Cited by 4
Self-citationWang, Z., Yang, X., Wei, X., Shi, L., Wang, X., Zhuo, Z., Su, H., Wu, W., & Cao, Y. J. (2025) · Theranostics · doi:10.7150/thno.103755 · Cited by 4
“Therefore, accurate identification of these components responsible for infection, progression and tumorigenesis allows for the simplification and optimization of vaccine formulation development [7, 8].”
Bacterial Genomes and Vaccine Design
Cafardi, V., Telford, J. L., & Serruto, D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5070-2_2 · Cited by 3
Vaccinology Is Turning into an Omics‐Based Science
Prachi, P., Biagini, M., & Bagnoli, F. (2012) · Drug Development Research · doi:10.1002/ddr.21048 · Cited by 4
“Studies done to date using the different approaches have generally shown a significant degree of overlap and have identified subsets of the surface and secreted antigens predicted by reverse vaccinology [Etz et al., 2002; Grifantini et al., 2002; Rodriguez-Ortega et al., 2006; Stranger-Jones et al., 2006; Doro et al.,…”
BackgroundImmunorelevant proteins for the diagnosis of bovine staphylococcal mastitis
Fabres-Klein, M. H., Klein, R. C., de Paula, S. O., & Ribon, A. D. O. B. (2013) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-013-1274-8 · Cited by 3
Vacinas derivadas da análise dos genomas: vacinologia reversa
Ferreira, R. J., & Porco, G. A. (2008) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 3
Müller, M. (2004) · KOPS (University of Konstanz) · Cited by 4
Hermans, K., Devriese, L. A., & Haesebrouck, F. (2004) · doi:10.1002/9780470344903.ch4 · Cited by 3
Finding Protective Bacterial Antigens
Grandi, G., & Nagy, E. (2012) · Springer eBooks · doi:10.1007/978-3-7091-0709-6_2 · Cited by 3
“Based on the cumulative data obtained for the ANTIGENomes of these species, nearly 50% of all antigens fell into four cellular role categories: cell wall, cellular processes, transport and binding proteins, and determinants of protein fate (mainly proteases) (Etz et al. 2002; Meinke et al. 2005; Giefing et al. 2008; F…”
BackgroundSelf-citationScreening of strain-specific Actinobacillus pleuropneumoniae genes using a combination method
Lei, L., Du, C., Yang, P., Xie, F., Ou, P., Han, W., & Wang, J. (2009) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2009.01.015 · Cited by 2
Puces à protéines : nouvelle approche du diagnostic des maladies infectieuses
Sakanyan, V. A. (2004) · Antibiotiques · doi:10.1016/s1294-5501(04)94261-6 · Cited by 2
Semiautomated design and soluble expression of a chimeric antigen TbpAB01 from Glaesserella parasuis
Chen, J., Zhou, L. Y., Gong, J., Wang, N., Miao, F., Su, C., Gao, X., Xu, G., Shi, J., & Xu, Z. (2024) · Biotechnology and Bioengineering · doi:10.1002/bit.28710 · Cited by 1
“Therefore, bacterial MP is a significant vaccine target that can trigger high titers of bactericidal antibodies (Ab) (Etz et al., 2002; Sparling et al., 1994).”
BackgroundFeng, M., Cui, J.-C., Nakane, A., & Hu, D. (2013) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.231.1 · Cited by 1
“The growing prevalence of antibiotic resistant S. aureus strains threatens the effectiveness of current strategies for managing S. aureus infection and demonstrates the need for other means of controlling and preventing staphylococcal infections (Etz et al. 2002; Sheen et al. 2011).”
BackgroundL’antivirulence : du concept aux applications
Desnottes, J. F. (2009) · Antibiotiques · doi:10.1016/j.antib.2008.12.002 · Cited by 1
Future Diagnostic and Therapeutic Approaches in Surgical Infections
Haas, B., & Nathens, A. B. (2009) · Surgical Clinics of North America · doi:10.1016/j.suc.2008.09.013 · Cited by 1
“Similar approaches have been used by other groups for S aureus and for S pneumoniae.(96,98,99)”
MethodRezaei, E., Khaki, P., Bidhendi, S. M., Noofeli, M., & Soltani, M. (2019) · Iranian Journal of Microbiology · doi:10.18502/ijm.v11i5.1955 · Cited by 1
“Therefore, it can be used in diagnostic tests and vaccine producing procedure (23, 24).”
BackgroundBidmos, F. A., Gladstone, C. A., & Langford, P. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00113-1 · Cited by 3
Vaccine‐Based Strategies for Prevention of Staphylococcus Aureus Infection
Schaffer, A. C., & Lee, J. C. (2009) · Staphylococci in Human Disease · doi:10.1002/9781444308464.ch32 · Cited by 1
Peacock, S. J. (2010) · Wiley eBooks · doi:10.1002/9780470688618.taw0032 · Cited by 1
L’antivirulence : du concept aux applications
Desnottes, J. F. (2009) · Antibiotiques · doi:10.1016/j.antib.2009.02.004 · Cited by 2
Identification and characterization of biomarkers in bacterial infections.
Storm, M. (2006) · Uppsala University Publications (Uppsala University) · Cited by 1
Movahedi, A. (2008) · Murdoch University Research Portal
Antigen Discovery for Vaccines Using High‐Throughput Proteomic Screening Technologies
Davies, D. H. (2012) · Wiley eBooks · doi:10.1002/9781118345313.ch10 · Cited by 2
Immune Response to Tuberculosis as a Basis for Rational Vaccination Strategies
Kaufmann, S. H. E., & Stenger, S. (2009) · Wiley eBooks · doi:10.1002/9783527627905.ch2 · Cited by 1
Characteristics of Staphylococcus aureus infections to consider in designing an effective vaccine.Preprint
Pastrana, F. R., Hernández-Jauregui, P., & Baca, B. E. (2010) · Nature Precedings · doi:10.1038/npre.2010.4598.1 · Cited by 2
“aureus antigens can be detected in all humans, and titers usually rise after infection (13, 16, 40).”
BackgroundWardenburg, J. B., Schneewind, O., & DeLeo, F. R. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir142
Kudva, I. T., Calderwood, S. B., & John, M. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2.8.979
Metadata
- Authors
- Etz, H., Minh, D. B., Henics, T., Dryla, A., Winkler, B., Triska, C., Boyd, A. P., Söllner, J., Schmidt, W., von Ahsen, U., Buschle, M., Gill, S. R., Kolonay, J., Khalak, H., Fraser, C. M., von Gabain, A., Nagy, E., & Meinke, A.
- Affiliations
- Intercell (Austria) (AT)
- InterCell Biomedizinische Forschungs- und Entwicklungs-AG, Campus Vienna Biocenter 6, 1030 Vienna, Austria; and Institute for Genomic Research, 9712 Medical Center Drive, Rockville, MD 20850
- Corresponding author
- Meinke, Andreas
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-05-07
- Volume
- 99
- Issue
- 10
- Pages
- 6573-6578
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC124444
- OpenAlex
- W1999985155
- Cited by
- 218
- References
- 21
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 9 · 2015: 7 · 2014: 9 · 2013: 9 · 2012: 13
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Structural Characterization
- Keywords
- Staphylococcus aureus, vaccine candidate antigens, subunit vaccine design, antigen identification, opsonic activity, lambs, FhuA, surface-exposed proteins, secreted proteins, whole genome sequencing, serological reactivity
- MeSH terms
- Amino Acid Sequence, Animals, Antigens, Bacterial, Bacterial Outer Membrane Proteins, Base Sequence, DNA, Bacterial, Humans, Macrophages, Mice, Inbred BALB C, Molecular Sequence Data, Phagocytosis, Receptors, Virus, Recombinant Fusion Proteins, Staphylococcal Infections, Staphylococcal Vaccines, Staphylococcus aureus, Vaccines, Synthetic, Genomic Library, Gene Expression, Genome, Bacterial, Porins, Epitopes, B-Lymphocyte, Escherichia coli Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.